相关临床试验
239
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1851
进行中（未招募）
9
3.8%
已完成
173
72.4%
Enrolling By Invitation
2
0.8%
尚未招募
7
2.9%
招募中
34
14.2%
暂停
3
1.3%
终止
8
3.4%
撤回
3
1.3%
暂无批准数据
- Florida State University's College of Nursing and College of Medicine received a more than $1.6 million NIH T32 Institutional National Research Service Award to train nurse scientists in digital health and AI. - The five-year NURTURe program will prepare nurse-trained postdoctoral fellows to develop, test, and apply digital health and AI tools for disease prevention and chronic condition management, with a focus on rural communities. - The program is based in the Institute on Digital Health and Innovation and supported by the College of Medicine's Center for Translational Behavioral Science, led by three multiple principal investigators. - The award advances FSU College of Nursing's broader leadership in AI-enabled healthcare, including the nation's first MSN concentration in AI Applications in Healthcare.
- Florida State University, through FSU Health, awarded $250,000 to five inaugural recipients of its Clinical Catalyst Grant Program to address urgent patient-care challenges through collaborative research. - The program pairs FSU researchers with local clinical providers, including Tallahassee Orthopedic Clinic, Capital Health Plan, and Tallahassee Memorial, to accelerate progress on community healthcare needs. - Funded projects span non-pharmacologic chronic pain management, nutrition support for aging adults, vagus nerve stimulation for stroke aphasia, post-mastectomy bra redesign, and advanced care directive uptake. - Vice President for Research Stacey S. Patterson emphasized the program's role in delivering innovative ideas that can make a meaningful difference in clinical practice and patient outcomes.
- 60 Degrees Pharmaceuticals has exercised its license option with Florida State University to develop large-scale purification techniques for castanospermine from Australian Chestnut seeds. - Castanospermine modulates carbohydrate metabolism at low doses and has shown therapeutic potential through immunomodulation in animal models. - The company has completed safety testing and prototype formulations, preparing to seek U.S. regulatory approval for Australian Chestnut Extract as a non-prescription botanical product. - Previous clinical trials of celgosivir, which produces castanospermine as a metabolite, demonstrated safety in over 500 patients with HIV and Hepatitis C.
- Human Continuum Inc. has appointed Dr. Omar Khalid Sial, Ph.D., as Chief Scientific Officer to lead development of innovative extracellular vesicle topical formulations and advanced biologics. - Dr. Sial brings over 13 years of experience in preclinical research and pharmaceutical drug development, with expertise in neuroscience, immunology, and genetics. - The company is developing a comprehensive platform of exosome-based therapeutics spanning longevity, orthopedics, aesthetics, and dermatology applications. - Human Continuum's lead program features an investigational IV infusion of standardized, cell-free, platelet-derived exosomes designed to modulate systemic inflammation and support cellular health.
- Florida becomes the first state to offer comprehensive newborn genetic screening through the Sunshine Genetics Pilot Program, providing free genetic sequencing to identify serious but treatable conditions before symptoms appear. - The initiative receives $7.5 million in state funding plus an additional $2 million from Florida State University, establishing the Institute for Pediatric Rare Diseases as the program's central hub. - The Sunshine Genetics Consortium unites Florida's top universities including FSU, UF, UM, USF, and FIU with hospitals and biotech companies to accelerate research and improve access to treatments for rare childhood diseases. - The program aims to end the "Diagnostic Odyssey" that families endure when seeking answers about rare diseases, with early diagnosis enabling proactive care and better outcomes for affected children.
- The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health. - Critical research projects halted include HIV prevention trials, studies on preventing suicide in transgender teens, and research on sexually transmitted diseases, leaving many labs forced to lay off staff. - Scientists and public health experts warn these cuts will harm healthcare for sexual and gender minorities, who make up nearly 10% of American adults, and could reverse progress in disease prevention.
